| MATERIAL S AND ME THODS

| Synthesis of DTPEP
The lead compound DTPEP and tamoxifen share structural similarity as shown in Figure 1A . DTPEP was synthesized, purified and characterized according to our previously reported method (supplementary data). 9 
| Plasmids
The 2xERE-pS2-bearing pGL3-luc plasmid, ERα (pSG5-mERα) plasmid and ERβ (pSG5-hERβ) plasmid were kind gifts from Prof Malcolm G. Parker, Imperial Cancer Research Fund, London, UK. 10 The pRLluc plasmid was procured from Promega (Wisconsin, Madison, USA). was maintained in DMEM phenol red supplemented with 10% horse serum, 100 ng/mL cholera toxin, 20 ng/mL epidermal growth factor, 500 ng/mL hydrocortisone and 10 μg/mL insulin. LA-7 (rat mammary cancer cell line) was maintained in DMEM phenol red supplemented with 10% FBS, 50 nmol/L hydrocortisone and 5 μg/mL bovine insulin.
| Cells and cell culture condition
| Primary cell culture from breast adenocarcinoma tissues
The study was ethically approved by the Institutional Human Ethics
Committee of King George's Medical University (6610/Ethics/R.
Cell-15) and CSIR-CDRI (CDRI/IEC/2017/A5). Breast cancer patients
were recruited at the Department of Surgery, King George's Medical University, Lucknow, India. Clinically and histologically confirmed ER-negative high-grade infiltrating ductal breast carcinoma tissue were only used for primary cell culture studies. Primary cell culture was carried out as per previously described method. 11 In brief, tissues were collected in DMEM-F12 containing antibiotic, minced and incubated with 1 mg/ml collagenase and DNase (2 mg/mL) in DMEM-F12 for 2 hours at 37°C with periodic mixing, digested tissue was mechanically dissociated by repeated pipetting and resuspended in 10 mL of fresh DMEM-F12. Suspension was cetrifuged and supernatant containing cells were separated from tissue clumps, washed twice with DMEM-F12 containing 10% FBS, transferred into culture flasks and incubated at 37°C with 5% CO 2 .
| MTT assay
MTT assay was carried out as previously described. 12 
| Colony formation assay
Cancer cells were seeded at the rate of 5000 cells per well in six-well culture plate and incubated overnight. Cells were treated with compound for 24 hours. Then, media along with compound were washed with PBS and incubated in fresh DMEM media for 7 days. At the end of incubation period, media were removed, cells were fixed with methanol, stained with 0.4% crystal violet and images were captured. 
| DAPI staining
Cells were seeded at a density of 10 000 cells per well in four-well glass chambers slide and grown overnight. Then, cells were treated with compound for 24 hours, washed and fixed with 4% paraformaldehyde. Cells were stained with DAPI (0.5 mg/mL) for 30 minutes at 37°C, observed under fluorescent microscope and image of random fields from each group were captured (Leica, Wetzlar, Hesse, Germany) using blue filter. 13 
| Cell cycle analysis
Cell cycle analysis was carried out as previously described. 14 The percentage of DNA content at different phases of the cell cycle was analysed using FACS Calibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA) and analysed with CellQuest software (Becton-Dickinson).
| Annexin V-FITC and PI staining
Assay was carried out as previously described using Annexin V-FITC and PI kit as per manufacturer instructions (Sigma, St. Louis, MO, USA). 15 Live, apoptotic and necrotic cell populations were differentiated using flow cytometer (Becton-Dickinson).
| Measurement of intracellular ROS
Cancer cells were plated in the density of 1 × 10 5 cells/well in sixwell culture plates for 24 hours. Cells were treated with compound for 24 hours and then cells were trypsinized, fixed in 1 mL methanol, stained with DCFH-DA stain (2 μg/mL) for 30 minutes at 37°C followed by PBS washing twice. The stained cells were measured for ROS accumulation using flow cytometer (Becton-Dickinson).
| Measurement of mitochondrial membrane potential
MMP assay was carried out as previously described. 16 The change in the MMP was estimated by calculating the ratio of fluorescence at 590 nm (green) and 530 nm (red).
| Western blotting
Cells from various treatment groups were washed with ice-cold PBS, lysed in RIPA buffer containing phosphatase and protease inhibitor cocktail (Sigma-Aldrich). Lysates containing equal amount of protein were electrophoresed and transferred to PVDF membrane (Millipore, Bangalore, Karnataka, India), probed with appropriate primary antibodies. Blots were developed using ECL solution (Immobilon; Millipore, Billerica, MA, USA) and scanned with gel documentation system (ImageQuant LAS4000, GE, Piscataway, NJ, USA). 17 Each experiment was repeated minimum three times.
Quantitation of band intensity was carried out by densitometry using Quantity One 1-D analysis software version 4.6.6 (Biorad, Hercules, California, USA).
| RT-PCR and quantitative real-time PCR
Total RNA was extracted from the cells of various treatment groups using Trizol (Invitrogen, Carlsbad, CA, USA). cDNA synthesized with RevertAid H Minus Reverse Transcriptase cDNA synthesis kit (Fermentas, Burlington, Ontario, Canada) using 2 μg of total RNA.
Quantitative PCR was performed for assessing the expression of selected genes using SYBR Green (Roche, Indianapolis, IN,). Relative gene expression levels were determined using quantitative real-time PCR (LightCycler480; Roche) and fold change in expression of different genes were determined after normalizing with 18S. 18 Experiments were repeated three times and data were expressed in mean fold change ±SE.
The details of primers used are shown in supplementary Table S1 . 
| Immunofluorescence staining
| Tunel assay
DeadEnd fluorometric TUNEL system (Promega; cat. no. G3250) was used for Tunel assay. DAPI-containing mounting media were used for mounting with coverslip and samples were analysed using fluorescence confocal microscope.
| Transient transfection and ER transactivation assay
For analysis of ERE-mediated transcription, MCF-7 cells were transfected with 100 ng of pERE-Luc using Lipofectamine-2000 ™ transfection reagent (Invitrogen). Then, 100 ng of ERα or ERβ expression plasmids was cotransfected with pERE-Luc in ER-negative MDA-MB-231 breast cancer cell line. In addition, 50 ng of pRL-SV40-luc was cotransfected for using it for normalization of transfection efficiencies. After 5 hours of transfection, cells were treated with vehicle, E 2 and different concentrations of DTPEP. After 18 hours, cells were processed using lysis buffer and then proceeded for luciferase activity measurement using Dual
Luciferase Assay System (Promega). The firefly luciferase intensity for every sample was normalized through transfection efficiency obtained from renilla luciferase activity. 23 Each experiments were performed in triplicate of each test groups with three replicates of each experiment.
| Statistical analysis
All the analysed results are expressed as mean ± SEM derived from at least three independent experiments with triplicates of each test group. Statistical significance was determined by ANOVA and Newmann-Keul's test or by paired Student's t test. The levels of probability were noted and P values <.05 were considered statistically significant. P-values were noted as, if significant P < .05 (*), P < .01 (**), P < .001 (***). Statistical analysis was carried out using Microsoft Excel and Prism software 5.0 (GraphPad Software, La Jolla, CA, USA). 
| RE SULTS
| DTPEP induces G0/G1 arrest, cellular ROS, apoptosis and altered MMP in breast cancer cells
| DTPEP-induced loss of MMP and apoptosis are ROS dependent
It is known that a majority of chemotherapeutic agents induces cellular ROS which in turn is responsible for mitochondria-mediated apoptosis. 24 . After gating out cell debris and aggregates, 10 000 events were collected for analysis of each sample. All values are expressed as mean with their standard errors (mean ± SEM, N = 3) derived from three independent cytometry assay and presented with histograms on corresponding right side panels. Statistical analysis of each parameter for the compound treated groups was compared with non-treated groups using one-way ANOVA (non-parametric) with NewmanKeuls post hoc test. The difference was considered statistically significant if *P < .05. **P < .01 and ***P < .001 vs control caspase-3 are indicator of activation of intrinsic apoptotic pathway.
| DTPEP induces caspase-dependent apoptosis
We found that DTPEP treatment significantly increased cleaved caspase-8, pro-caspase Bax, cytochrome c and significantly de- Renilla luciferase pRL-luc plasmid was used for internal control. Results are described as % of normalized relative luciferase unit (RLU). Results are expressed as mean ± SEM, n = 3. P values are a-P < .001, b-P < .01, c-P < .05 and d-P > .05 vs control and e-P < .001, f-P < .01, g-P < .05 and h-P > .05 vs E 2 . Primary antibodies used Phospho-Oestrogen Receptor α (Ser118) (cat. 251, cst), p21 (cat. 2947, cst), ERα (MC-20) (cat.sc-542) and ERβ (cat.sc-8974), PR, (cat. sc-528), PCNA (cat.sc-53407) and β-actin (cat. 4970, cst) transcription 25 ( Figure 5D ,E). These data suggest that DTPEP induces dose-dependent decrease in expression of ERα along with concomitant increase in expression of ERβ which correlates with DTPEP-induced inhibition of MCF-7 proliferation. DTPEP also significantly decreased ERE-mediated transcription in concentrationdependent manner as compared to control ( Figure 5I ). Decrease in ERE-mediated transcription was significant even at 1 μmol/L in DTPEP + E 2 treated group in comparison to E 2 (P < .001) indicating that the compound acts by antagonizing E 2 by stimulating transcription via classical (ERE-mediated) pathway ( Figure 5I ).
Overall, these data suggest that DTPEP action on MCF-7 cell is ER-dependent. To further assess specific involvement of ERα or ERβ, their expression plasmids were cotransfected with pERE-Luc plasmids in ER-negative MDA-MB-231 cells. Here, DTPEP caused a significant decrease in ERα-mediated ERE promoter activity both in the presence and absence of E 2 ( Figure 5J ). In case of E 2 -treated group, the decrease observed was significant even at 1 μmol/L (P < .01) in comparison to control and in comparison to E 2 (P < .001). However, DTPEP in the presence of E 2 -augmented ERβ-mediated ERE transactivation in a concentration-dependent manner (P > .05-.001) ( Figure 5J ). Thus, the results suggested that DTPEP acts through modulation of both ERα-and ERβ-mediated classical oestrogen signalling pathways in breast cancer cells.
| DTPEP downregulates PKCα and PI3K/Akt survival pathway in breast cancer cells
Furthermore, DTPEP significantly decreased total apoptosis in the presence of E 2 as compared to in the absence of E 2 in MCF-7 cells, but there is no significant decrease in MDA-MB-231 cells ( Figure 6A,B) .
Effect of DTPEP and TAM on non-ER pathway of apoptosis of breast cancer cell (A) MCF-7 cells and (B) MDA-MB-231 cell. Statistical analysis of each parameter for the DTPEP and tamoxifen treated in the presence of E 2 groups was compared with DTPEP and tamoxifen alone treated groups using one-way ANOVA (non-parametric) with Newman-Keuls post hoc test. The difference was considered statistically significant if *P < .05, **P < .01 l and ***P < .001 DTPEP and tamoxifen in the presence of E 2 vs DTPEP and tamoxifen alone treated group. NS = not significant. Oral administration of DTPEP does not disrupt absolute organ weight (E), relative organ weight (F), total body weight (G) and total body weight gain (H). Statistical analysis of each parameter for the compound-treated groups was compared with non-treated groups using one-way ANOVA (non-parametric) with Newman-Keuls post hoc test. The difference was considered statistically significant if *P < .05. **P < .01 and ***P < .001 vs control
Thus, it suggests that DTPEP-induced apotosis in ER-positive MCF-7 cells can be partly countered by E 2, but DTPEP-induced apotosis in ERnegative MDA-MB-231 cells indicate that it may interact with cellular target other than ER. Previous studies report that tamoxifen downregulates PKCα which is considered as its non-ER-mediated action. This is CDRI communication no. 9700.
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